This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Catabasis (CATB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Catabasis (CATB) Stock?
by Zacks Equity Research
Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.
Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Catabasis (CATB) Partners with UK-Based Charity for DMD Study
by Zacks Equity Research
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
Vertex Expands Collaboration With CRISPR, Acquires Exonics
by Zacks Equity Research
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
Top Ranked Momentum Stocks to Buy for April 12th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 12th.
Sarepta (SRPT) Reports Positive Interim Results for DMD Drug
by Zacks Equity Research
Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.
Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
by Zacks Equity Research
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
Will Catabasis Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Catabasis.
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
by Zacks Equity Research
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
Rising P/E an Overlooked Criterion: 5 Top Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.
Catabasis (CATB) Beats Earnings in Q4, Revenues Nil
by Zacks Equity Research
Catabasis (CATB) beats earnings estimates in the fourth quarter of 2018. The company has no revenues. Shares up.
Townsquare (TSQ) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Townsquare's (TSQ) fourth-quarter 2018 results are expected to benefit from higher political revenues.
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
Is a Beat in Store for Catabasis (CATB) This Earnings Season?
by Zacks Equity Research
Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.
Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Catabasis Pharmaceuticals, Inc. (CATB) has been struggling lately, but the selling pressure may be coming to an end soon.
Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CATB) Outperforming Other Medical Stocks This Year?
Agenus (AGEN) Surges: Stock Moves 9.4% Higher
by Zacks Equity Research
Agenus (AGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
New Strong Buy Stocks for December 13th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
by Indrajit Bandyopadhyay
Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.
DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus
by Indrajit Bandyopadhyay
Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up
by Zacks Equity Research
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.